CSIMarket
 

Regencell Bioscience Holdings Limited  (NASDAQ: RGC)

Regencell Bioscience Holdings Limited's Working Capital Per Sales

RGC's Working Capital and Revenue growth





RGC Working Capital Per Revenue (Jun 30 2025)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Jun 30 2023)
IV. Quarter
Y / Y Working Capital Change -61.51 % -61.51 % -61.51 % -61.51 % -30.58 %
Y / Y Revenue Change - - - - -
Working Capital Per Revenue - - - - -
Working Capital Per Revenue Ranking # # # # #
Seq. Working Capital Change 0 % 0 % 0 % -61.51 % 0 %
Seq. Revenue Change - - - - -





Comment on RGC's Working Capital Per Revenue in the fourth quarter 2025


Within Consumer Non Cyclical sector Regencell Bioscience Holdings Limited has achieved the lowest Working Capital Per Revenue. While Working Capital Per Revenue remained unchanged in the Q4 2025 relative to the prior quarter at no. .
Working Capital Per Revenue Ranking
Within: No.
Industry #
Sector #
S&P 500 #


Working Capital Per Revenue Statistics
High Average Low
0
0
0
 



Financial Statements
Regencell Bioscience Holdings Limited's Working Capital $ 4 Millions Visit RGC's Balance sheet
Regencell Bioscience Holdings Limited's Revenues $ 0 Millions Visit RGC's Income Statement
Where are RGC's Sales coming from? Visit RGC's Sales by Geography




Companies with similar Average Working Capital Per Revenue for 12 months ending Jun 30 2025, within Consumer Non Cyclical Sector Working Capital Per Revenue
Date modified: 2025-11-01T05:56:14+00:00



Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.